Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01076530
Other study ID # NCI-2011-02011
Secondary ID ADVL0819CDR00006
Status Completed
Phase Phase 1
First received February 25, 2010
Last updated May 1, 2013
Start date February 2010

Study information

Verified date May 2013
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating young patients with relapsed or refractory primary brain tumors or spinal cord tumors. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may help temozolomide work better by making tumor cells more sensitive to the drug.


Description:

PRIMARY OBJECTIVES:

I. To estimate the maximum tolerated dose and/or recommended phase II dose of vorinostat in combination with temozolomide in pediatric patients with relapsed or refractory primary CNS tumors.

II. To define and describe the toxicities of this regimen in these patients.

SECONDARY OBJECTIVES:

I. To preliminarily define the antitumor activity of this regimen within the confines of a phase I study.

II. To characterize the pharmacokinetic parameters of vorinostat in these patients.

III. To determine whether acetylated histones in peripheral blood mononuclear cells can be identified as a surrogate marker of the biologic effect of vorinostat at various treatment doses.

IV. To assess the feasibility of collecting and analyzing serum DNA for methylation of the MGMT promoter and describe the relationship between promoter methylation and clinical responses within the confines of this phase I study.

OUTLINE: This is a multicenter, dose-escalation study of vorinostat.

Patients receive oral vorinostat and oral temozolomide once daily on days 1-5. Courses repeat every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.

Patients may undergo blood sample collection periodically for pharmacokinetic and correlative laboratory studies by western blotting and MGMT promoter methylation assays.

After completion of study therapy, patients are followed up for 30 days.


Recruitment information / eligibility

Status Completed
Enrollment 27
Est. completion date
Est. primary completion date October 2012
Accepts healthy volunteers No
Gender Both
Age group 1 Year to 21 Years
Eligibility Inclusion Criteria:

- Histologically confirmed CNS malignancy at original diagnosis or relapse

- Histologic confirmation not required for patients with intrinsic brain stem tumors, optic pathway gliomas, or pineal tumors provided CSF or serum tumor markers, including alpha-fetoprotein orbeta-HCG, are elevated

- Recurrent or refractory spinal cord tumors allowed

- Measurable or evaluable disease

- No known curative therapy or therapy proven to prolong survival with an acceptable quality of life

- Karnofsky performance status (PS) 50-100% (for patients > 16 years of age) OR Lansky PS 50-100% (for patients = 16 years of age)

- Neurological deficits must have been relatively stable for = 1 week before study entry

- Patients unable to walk due to paralysis, but who are up in a wheelchair, are considered ambulatory for the purpose of assessing performance status

- ANC = 1,000/µL

- Platelet count = 100,000/µL (transfusion independent, defined as no platelet transfusion within the past 7 days)

- Hemoglobin = 8.0 g/dL (RBC transfusions allowed)

- Creatinine clearance or radioisotope GFR = 70mL/min OR maximum serum creatinine based on age and/or gender as follows:

- 0.6 mg/dL (1 year of age)

- 0.8 mg/dL (2 to 5 years of age)

- 1.0 mg/dL (6 to 9 years of age)

- 1.2 mg/dL (10 to 12 years of age)

- 1.5 mg/dL (males) or 1.4 mg/dL (females) (13 to 15 years of age)

- 1.7 mg/dL (males) or 1.4 mg/dL (females) (= 16 years of age)

- Bilirubin = 1.5 times upper limit of normal

- ALT = 110 U/L

- Serum albumin = 2 g/dL

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Able to swallow capsules or liquid

- Seizure disorder allowed provided it is well controlled with nonenzyme-inducing anticonvulsants

- No pre-existing QTc = 450 msec

- No uncontrolled infection

- No patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of study

- Fully recovered from prior chemotherapy, immunotherapy, or radiotherapy

- More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosourea)

- At least 7 days since prior hematopoietic growth factors

- At least 7 days since prior biologic agent (antineoplastic agent)

- At least 7 days or 3 half-lives, whichever is longer, since prior monoclonal antibodies

- More than 2 weeks since prior local palliative radiotherapy (small port)

- At least 6 months since prior total-body radiotherapy (TBI), craniospinal radiotherapy, or radiotherapy to = 50% of the pelvis

- At least 6 weeks since other prior substantial bone marrow radiotherapy

- At least 3 months since prior stem cell transplantation or rescue (without TBI)

- No evidence of active graft-vs-host disease

- At least 2 weeks since prior valproic acid

- No prior vorinostat

- Prior temozolomide allowed provided there was no progressive disease during or within 1 month after completion of treatment

- Concurrent corticosteroids allowed provided patient has been on a stable or decreasing dose for = 7 days before study entry

- No other concurrent investigational drugs

- No other concurrent anticancer agents, including chemotherapy, radiotherapy, immunotherapy, or biologic therapy

- No concurrent enzyme-inducing anticonvulsants

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Astrocytoma
  • Childhood Atypical Teratoid/Rhabdoid Tumor
  • Childhood Central Nervous System Choriocarcinoma
  • Childhood Central Nervous System Embryonal Tumor
  • Childhood Central Nervous System Germinoma
  • Childhood Central Nervous System Mixed Germ Cell Tumor
  • Childhood Central Nervous System Teratoma
  • Childhood Central Nervous System Yolk Sac Tumor
  • Childhood Choroid Plexus Tumor
  • Childhood Craniopharyngioma
  • Childhood Ependymoblastoma
  • Childhood Grade I Meningioma
  • Childhood Grade II Meningioma
  • Childhood Grade III Meningioma
  • Childhood High-grade Cerebellar Astrocytoma
  • Childhood High-grade Cerebral Astrocytoma
  • Childhood Infratentorial Ependymoma
  • Childhood Low-grade Cerebellar Astrocytoma
  • Childhood Low-grade Cerebral Astrocytoma
  • Childhood Medulloepithelioma
  • Childhood Mixed Glioma
  • Childhood Oligodendroglioma
  • Childhood Supratentorial Ependymoma
  • Choriocarcinoma
  • Choroid Plexus Neoplasms
  • Craniopharyngioma
  • Ependymoma
  • Extra-adrenal Paraganglioma
  • Glioma
  • Medulloblastoma
  • Meningioma
  • Neoplasms
  • Neoplasms, Germ Cell and Embryonal
  • Neuroectodermal Tumors
  • Neuroectodermal Tumors, Primitive
  • Oligodendroglioma
  • Optic Nerve Glioma
  • Paraganglioma
  • Recurrent Childhood Brain Stem Glioma
  • Recurrent Childhood Central Nervous System Embryonal Tumor
  • Recurrent Childhood Cerebellar Astrocytoma
  • Recurrent Childhood Cerebral Astrocytoma
  • Recurrent Childhood Ependymoma
  • Recurrent Childhood Medulloblastoma
  • Recurrent Childhood Pineoblastoma
  • Recurrent Childhood Spinal Cord Neoplasm
  • Recurrent Childhood Subependymal Giant Cell Astrocytoma
  • Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
  • Recurrent Childhood Visual Pathway and Hypothalamic Glioma
  • Rhabdoid Tumor
  • Spinal Cord Neoplasms

Intervention

Drug:
vorinostat

temozolomide

Other:
diagnostic laboratory biomarker analysis

pharmacological study


Locations

Country Name City State
Canada Hospital Sainte-Justine Montreal Quebec
Canada Hospital for Sick Children Toronto Ontario
United States C S Mott Children's Hospital Ann Arbor Michigan
United States Childrens Memorial Hospital Chicago Illinois
United States Baylor College of Medicine Houston Texas
United States St. Jude Children's Research Hospital Memphis Tennessee
United States University of Minnesota Medical Center-Fairview Minneapolis Minnesota
United States Oregon Health and Science University Portland Oregon
United States Seattle Children's Hospital Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose defined as the maximum dose at which fewer than one-third of patients experience DLT using NCI CTCAE version 4.0 In addition to determination of the MTD, a descriptive summary of all toxicities will be reported. 28 days Yes
Primary Pharmacokinetic parameters of vorinostat in combination with temozolomide The PK parameters will be summarized with simple summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit). Pre-dose, 15 and 30 minutes, 1, 2, 4, 6, 8, and 24 hours No
Secondary Response assessed according to RECIST criteria Will be reported descriptively. Up to 30 days No
See also
  Status Clinical Trial Phase
Withdrawn NCT02194452 - Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors N/A
Completed NCT00053963 - FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Phase 1
Active, not recruiting NCT03233204 - Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Phase 2
Completed NCT00095940 - Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors Phase 1/Phase 2
Completed NCT00091182 - Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Phase 2
Completed NCT00052780 - Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors Phase 1
Completed NCT00004078 - Irinotecan in Treating Children With Refractory Solid Tumors Phase 2
Completed NCT00100880 - Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors Phase 1
Recruiting NCT02359565 - Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma Phase 1
Terminated NCT01088763 - Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Phase 1
Completed NCT00326664 - AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors Phase 1
Completed NCT00101270 - Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas Phase 1
Active, not recruiting NCT03210714 - Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Completed NCT00363272 - Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma Phase 1
Completed NCT00946335 - ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors Phase 1
Completed NCT00063973 - Cilengitide in Treating Children With Refractory Primary Brain Tumors Phase 1
Completed NCT01462695 - Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Phase 2
Completed NCT03387020 - Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors Phase 1
Active, not recruiting NCT00638898 - Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor Phase 1
Recruiting NCT05857969 - Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling